Isocitrate Dehydrogenase

"Isocitrate Dehydrogenase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An enzyme of the oxidoreductase class that catalyzes the conversion of isocitrate and NAD+ to yield 2-ketoglutarate, carbon dioxide, and NADH. It occurs in cell mitochondria. The enzyme requires Mg2+, Mn2+; it is activated by ADP, citrate, and Ca2+, and inhibited by NADH, NADPH, and ATP. The reaction is the key rate-limiting step of the citric acid (tricarboxylic) cycle. (From Dorland, 27th ed) (The NADP+ enzyme is EC 1.1.1.42.) EC 1.1.1.41.

Descriptor ID	D007521
MeSH Number(s)	D08.811.682.047.820.475
Concept/Terms	Isocitrate Dehydrogenase Isocitrate Dehydrogenase Dehydrogenase, Isocitrate NAD Isocitrate Dehydrogenase Dehydrogenase, NAD Isocitrate Isocitrate Dehydrogenase, NAD Isocitrate Dehydrogenase (NAD+) Isocitrate Dehydrogenase-I Isocitrate Dehydrogenase-I Isocitrate Dehydrogenase I

Below are MeSH descriptors whose meaning is more general than "Isocitrate Dehydrogenase".

Chemicals and Drugs [D]
Enzymes and Coenzymes [D08]
Enzymes [D08.811]
Oxidoreductases [D08.811.682]
Alcohol Oxidoreductases [D08.811.682.047]
NAD (+) and NADP (+) Dependent Alcohol Oxidoreductases [D08.811.682.047.820]
Isocitrate Dehydrogenase [D08.811.682.047.820.475]

Below are MeSH descriptors whose meaning is related to "Isocitrate Dehydrogenase".

Below are MeSH descriptors whose meaning is more specific than "Isocitrate Dehydrogenase".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Isocitrate Dehydrogenase" by people in this website by year, and whether "Isocitrate Dehydrogenase" was a major or minor topic of these publications.

Bar chart showing 21 publications over 8 distinct years, with a maximum of 5 publications in 2024

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2012	0	1	1
2015	1	3	4
2016	2	0	2
2018	1	1	2
2020	0	1	1
2022	1	3	4
2024	5	0	5
2025	1	1	2

Below are the most recent publications written about "Isocitrate Dehydrogenase" by people in Profiles.

Tamir TY, Chaudhary S, Li AX, Trojan SE, Flower CT, Vo P, Cui Y, Davis JC, Mukkamala R, Venditti FN, Hillis AL, Toker A, Vander Heiden MG, Spinelli JB, Kennedy NJ, Davis RJ, White FM. Structural and systems characterization of phosphorylation on metabolic enzymes identifies sex-specific metabolic reprogramming in obesity. Mol Cell. 2025 Jun 05; 85(11):2211-2229.e8.

View in: PubMed
Bono BC, Grimi A, Di Toro AE, Ninatti G, Franzini A, Rossini Z, Tropeano MP, Navarria P, Bellu L, Simonelli M, Dipasquale A, Savini G, Levi R, Politi LS, Pessina F, Riva M. Preoperative Diffusion Tensor Imaging and Neurite Dispersion and Density Imaging in Isocitrate Dehydrogenase-Mutant Grade 2 and 3 Gliomas: Definition of Tumor-Related Epilepsy and Predictive Factors of Seizure Outcomes Based on a Single-Center Retrospective Case Series. Neurosurgery. 2025 Jan 29; 97(2):361-373.

View in: PubMed
Norman M, Yamartino K, Gerstein R, Shallis R, Mendez L, Podoltsev N, Stahl M, Eighmy W, Zeidan AM. A review of the isocitrate dehydrogenase inhibitors in management of adult patients with AML and MDS. Expert Rev Hematol. 2024 Nov; 17(11):755-767.

View in: PubMed
Ponomarova O, Starbard AN, Belfi A, Anderson AV, Sundaram MV, Walhout AJ. idh-1 neomorphic mutation confers sensitivity to vitamin B12 in Caenorhabditis elegans. Life Sci Alliance. 2024 Oct; 7(10).

View in: PubMed
Wu MJ, Kondo H, Kammula AV, Shi L, Xiao Y, Dhiab S, Xu Q, Slater CJ, Avila OI, Merritt J, Kato H, Kattel P, Sussman J, Gritti I, Eccleston J, Sun Y, Cho HM, Olander K, Katsuda T, Shi DD, Savani MR, Smith BC, Cleary JM, Mostoslavsky R, Vijay V, Kitagawa Y, Wakimoto H, Jenkins RW, Yates KB, Paik J, Tassinari A, Saatcioglu DH, Tron AE, Haas W, Cahill D, McBrayer SK, Manguso RT, Bardeesy N. Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity. Science. 2024 07 12; 385(6705):eadl6173.

View in: PubMed
Pitarresi JR, Fitzgerald KA. Unmasking immune suppression. Science. 2024 07 12; 385(6705):140-142.

View in: PubMed
Tropeano MP, Raspagliesi L, Bono BC, Baram A, Rossini Z, Franzini A, Navarria P, Clerici E, Bellu L, Simonelli M, Scorsetti M, Riva M, Politi LS, Pessina F. Supramaximal resection: retrospective study on IDH-wildtype Glioblastomas based on the new RANO-Resect classification. Acta Neurochir (Wien). 2024 04 27; 166(1):196.

View in: PubMed
Notarangelo G, Spinelli JB, Perez EM, Baker GJ, Kurmi K, Elia I, Stopka SA, Baquer G, Lin JR, Golby AJ, Joshi S, Baron HF, Drijvers JM, Georgiev P, Ringel AE, Zaganjor E, McBrayer SK, Sorger PK, Sharpe AH, Wucherpfennig KW, Santagata S, Agar NYR, Suv? ML, Haigis MC. Oncometabolite d-2HG alters T cell metabolism to impair CD8+ T cell function. Science. 2022 09 30; 377(6614):1519-1529.

View in: PubMed
Wu MJ, Shi L, Merritt J, Zhu AX, Bardeesy N. Biology of IDH mutant cholangiocarcinoma. Hepatology. 2022 05; 75(5):1322-1337.

View in: PubMed
Wu MJ, Shi L, Dubrot J, Merritt J, Vijay V, Wei TY, Kessler E, Olander KE, Adil R, Pankaj A, Tummala KS, Weeresekara V, Zhen Y, Wu Q, Luo M, Shen W, Garc?a-Beccaria M, Fern?ndez-Vaquero M, Hudson C, Ronseaux S, Sun Y, Saad-Berreta R, Jenkins RW, Wang T, Heikenw?lder M, Ferrone CR, Goyal L, Nicolay B, Deshpande V, Kohli RM, Zheng H, Manguso RT, Bardeesy N. Mutant IDH Inhibits IFN?-TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma. Cancer Discov. 2022 03 01; 12(3):812-835.

View in: PubMed

People

Explore

Similar Concepts

Top Journals